BSX:NYE-Boston Scientific Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 73.17

Change

0.00 (0.00)%

Market Cap

USD 28.38B

Volume

8.79M

Analyst Target

USD 46.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Boston Scientific Corp is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.76 (-0.73%)

USD 182.21B
SYK Stryker Corporation

-0.26 (-0.08%)

USD 126.53B
MDT Medtronic PLC

+0.78 (+0.93%)

USD 109.89B
EW Edwards Lifesciences Corp

+1.76 (+2.08%)

USD 51.28B
ZBH Zimmer Biomet Holdings Inc

+0.38 (+0.32%)

USD 24.98B
PHG Koninklijke Philips NV ADR

N/A

USD 24.22B
STE STERIS plc

+3.44 (+1.48%)

USD 20.76B
SNN Smith & Nephew SNATS Inc

+0.66 (+2.63%)

USD 10.96B
GMED Globus Medical

-0.91 (-1.43%)

USD 8.74B
BIO Bio-Rad Laboratories Inc

+8.57 (+3.00%)

USD 8.36B

ETFs Containing BSX

UMDV:SW iShares US Medical Device.. 8.50 % 0.00 %

-0.02 (-0.30%)

USD 0.25M
EDOC:AU BetaShares Digital Health.. 8.26 % 0.00 %

N/A

N/A
GDOC Goldman Sachs ETF Trust 6.08 % 0.00 %

+0.18 (+-0.30%)

USD 0.03B
EUPA:XETRA Ossiam Shiller Barclays C.. 4.97 % 0.00 %

+0.70 (+-0.30%)

USD 0.03B
EUPB:XETRA Ossiam Shiller Barclays C.. 4.97 % 0.00 %

+0.38 (+-0.30%)

USD 0.03B
5OGE:PA Ossiam Shiller Barclays C.. 4.97 % 0.00 %

+1.06 (+-0.30%)

N/A
5OGE:SW Ossiam Shiller Barclays C.. 4.97 % 0.00 %

N/A

USD 3.92M
5OGU:SW Ossiam Shiller Barclays C.. 4.97 % 0.00 %

+0.18 (+-0.30%)

USD 0.03B
XYLP:LSE Global X S&P 500® Covere.. 4.26 % 0.00 %

-0.04 (-0.30%)

USD 0.01B
XY7D:XETRA Global X S&P 500® Covere.. 4.21 % 0.00 %

-0.03 (-0.30%)

N/A
MHCD:CA Middlefield Healthcare Di.. 4.14 % 0.00 %

N/A

CAD 0.16B
XYLU:LSE Global X S&P 500® Covere.. 3.89 % 0.00 %

+0.01 (+-0.30%)

USD 0.02B
BMED BlackRock Future Health E.. 3.47 % 0.00 %

+0.22 (+-0.30%)

USD 4.21M
AGNG Global X Aging Population.. 3.18 % 0.00 %

+0.28 (+-0.30%)

USD 0.06B
ASWE:XETRA Saturna Al-Kawthar Global.. 3.00 % 0.00 %

+0.03 (+-0.30%)

USD 0.01B
AMAL:LSE Saturna Al-Kawthar Global.. 2.98 % 0.00 %

+0.03 (+-0.30%)

USD 0.01B
AMAP:LSE Saturna Al-Kawthar Global.. 2.96 % 0.00 %

+0.55 (+-0.30%)

USD 0.01B
BKUS 2.89 % 0.00 %

N/A

N/A
TDOC:CA TD Global Healthcare Lead.. 2.51 % 0.00 %

+0.04 (+-0.30%)

CAD 0.08B
PLDR Putnam Sustainable Leader.. 2.49 % 0.00 %

+0.18 (+-0.30%)

USD 0.50B
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

+0.03 (+-0.30%)

USD 0.05B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

+0.03 (+-0.30%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

-0.01 (-0.30%)

N/A
BTHM BlackRock ETF Trust - Bla.. 2.19 % 0.00 %

+0.15 (+-0.30%)

USD 7.03M
XMLH:XETRA L&G Healthcare Breakthrou.. 2.00 % 0.00 %

+0.09 (+-0.30%)

USD 0.07B
2B78:XETRA iShares Healthcare Innova.. 2.00 % 0.00 %

+0.04 (+-0.30%)

USD 1.14B
DRDR:LSE iShares Healthcare Innova.. 1.98 % 0.00 %

+2.75 (+-0.30%)

USD 1.07B
DOCG:LSE L&G Healthcare Breakthrou.. 1.96 % 0.00 %

+7.05 (+-0.30%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.96 % 0.00 %

+0.12 (+-0.30%)

USD 0.07B
HEAL:LSE iShares Healthcare Innova.. 1.78 % 0.00 %

+0.06 (+-0.30%)

USD 1.07B
HEAL:SW iShares Healthcare Innova.. 1.78 % 0.00 %

+0.07 (+-0.30%)

N/A
RSPH Invesco S&P 500® Equal.. 1.77 % 0.00 %

+0.25 (+-0.30%)

USD 1.02B
XMLH:F Legal & General Ucits Etf.. 1.76 % 0.00 %

+0.10 (+-0.30%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.76 % 0.00 %

+0.10 (+-0.30%)

USD 0.07B
W311:XETRA HAN-GINS Indxx Healthcare.. 1.39 % 0.00 %

+0.05 (+-0.30%)

USD 0.02B
WELL:LSE Hanetf Icav - Han-Gins He.. 1.38 % 0.00 %

+0.05 (+-0.30%)

USD 0.02B
DXQ:CA Dynamic Active Enhanced Y.. 1.38 % 0.00 %

+0.03 (+-0.30%)

CAD 0.53B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.37 % 0.00 %

+4.95 (+-0.30%)

USD 0.02B
OPEN:LSE iShares Thomson Reuters I.. 1.29 % 0.00 %

+0.01 (+-0.30%)

USD 0.06B
DTEC ALPS Disruptive Technolog.. 1.26 % 0.00 %

+0.20 (+-0.30%)

USD 0.10B
GENE:LSE UBS (Irl) ETF Public Limi.. 1.24 % 0.00 %

-2.70 (-0.30%)

USD 0.10B
GENG:LSE UBS (Irl) ETF plc - Globa.. 1.24 % 0.00 %

-0.25 (-0.30%)

USD 0.04B
GGUE:XETRA UBS Global Gender Equalit.. 1.24 % 0.00 %

-0.03 (-0.30%)

USD 0.23B
W311:F HAN-GINS Indxx Healthcare.. 1.23 % 0.00 %

+0.05 (+-0.30%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.23 % 0.00 %

+0.05 (+-0.30%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.23 % 0.00 %

+0.06 (+-0.30%)

N/A
AGES:LSE iShares IV Public Limited.. 0.66 % 0.00 %

-0.13 (-0.30%)

USD 0.47B
AGED:LSE iShares Ageing Population.. 0.66 % 0.00 %

+0.04 (+-0.30%)

USD 0.47B
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.22 (+-0.30%)

USD 5.29B
LNGR 0.00 % 0.50 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

+0.31 (+-0.30%)

USD 0.06B
RYH 0.00 % 0.40 %

N/A

N/A
BSCU Invesco BulletShares 2030.. 0.00 % 0.00 %

+0.03 (+-0.30%)

USD 0.70B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

+0.02 (+-0.30%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 26.57% 91% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.57% 91% A- 95% A
Trailing 12 Months  
Capital Gain 40.39% 81% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.39% 81% B- 88% B+
Trailing 5 Years  
Capital Gain 97.12% 95% A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.12% 95% A 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 10.03% 65% D 71% C-
Dividend Return 10.03% 61% D- 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.78% 97% N/A 62% D
Risk Adjusted Return 56.42% 90% A- 81% B-
Market Capitalization 28.38B 91% A- 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 357.70 35% 10%
Price/Book Ratio 5.19 31% 17%
Price / Cash Flow Ratio 42.97 18% 5%
Price/Free Cash Flow Ratio 31.54 9% 6%
Management Effectiveness  
Return on Equity 8.58% 84% 52%
Return on Invested Capital 7.11% 76% 53%
Return on Assets 4.47% 81% 68%
Debt to Equity Ratio 44.43% 55% 64%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.